With an FDA decision drawing near for testosterone gel Fortesta, Endo Pharmaceuticals Inc. has grabbed marketing rights to the hormone replacement therapy in the U.S. under a deal valued at up to $210 million with U.K.-based Prostrakan Group plc. (BioWorld Today) Read More
